Background: World Health Organization grade II astrocytomas (AII) are the commonest low-grade glioma subset, but their prognostic factors are subject to debate. This institutional study aimed to identify prognostic factors in lobar AII.
Methods: Retrospective review of newly diagnosed, lobar AII between 2006 and 2012. Patient demographics, imaging, and treatment data were obtained. Isocitrate dehydrogenase-1 (IDH1) status was assessed via immunohistochemistry. Multivariate analysis was performed with Cox regression to identify prognostic factors for overall survival (OS) and progression-free survival (PFS).
Results: A total of 92 adult patients were identified with a median age of 42 years (range 20-73 years) and median follow-up period of 45 months (range, 7-98 months). Seizures were the commonest mode of presentation (75%). IDH1 immunopositivity was seen in 46 of 83 patients (55%). Radiology diagnosis agreed with histology in 76% of cases, and 28% of tumors had documented evidence of some degree of contrast enhancement. Surgical management was either resection (51%) or biopsy (49%) and postoperative radiotherapy was used in patients with unfavorable prognostic features. The median OS and PFS were 85 months (range 2-98 months) and 36 months (95% confidence interval [95% CI] 27-45 months), respectively. Surgical resection (P < 0.001; hazard ratio [HR] 5.072; 95% CI 2.050-12.550), absence of contrast enhancement (P = 0.006; HR 3.180; 95% CI 1.403-7.206), and IDH1 immunopositivity (P = 0.006; HR 3.310; 95% CI 1.416-7.738) were associated with improved OS. Good performance status (P = 0.005; HR 5.965; 95% CI 1.710-20.804) and absence of contrast enhancement (P < 0.001; HR 3.446; 95% CI 1.883-6.304) were associated with improved PFS.
Conclusions: Patients with World Health Organization grade II astrocytomas have better overall survival if their tumor is nonenhancing, amenable to surgical resection, and exhibits the IDH1 mutation. These factors should be used to guide patient management and inform prognosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.wneu.2015.02.045 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Highly multiplexed imaging reveals prognostic immune and stromal spatial biomarkers in breast cancer.
JCI Insight
January 2025
Department of Biomedical Engineering, Oregon Health and Science University, Portland, United States of America.
Spatial profiling of tissues promises to elucidate tumor-microenvironment interactions and generate prognostic and predictive biomarkers. We analyzed single-cell, spatial data from three multiplex imaging technologies: cyclic immunofluorescence (CycIF) data we generated from 102 breast cancer patients with clinical follow-up, and publicly available imaging mass cytometry and multiplex ion-beam imaging datasets. Similar single-cell phenotyping results across imaging platforms enabled combined analysis of epithelial phenotypes to delineate prognostic subtypes among estrogen-receptor positive (ER+) patients.
View Article and Find Full Text PDFTiming of neuroprognostication in the ICU.
Curr Opin Crit Care
January 2025
Department of Critical Care Medicine.
Purpose Of Review: Neuroprognostication after acute brain injury (ABI) is complex. In this review, we examine the threats to accurate neuroprognostication, discuss strategies to mitigate the self-fulfilling prophecy, and how to approach the indeterminate prognosis.
Recent Findings: The goal of neuroprognostication is to provide a timely and accurate prediction of a patient's neurologic outcome so treatment can proceed in accordance with a patient's values and preferences.
Tetraspanins CD63 and CD81 as potential prognostic biomarkers in breast cancer.
Breast Cancer
January 2025
Department of Pathology and Histotechnology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Exosome markers, CD63 and CD81, belong to the tetraspanin family and are expressed in solid tumors. It has been reported that these tetraspanin family members are prognostic factors in some cancers. However, the expression of CD63 and CD81 in pathological breast cancer specimens has not been reported.
View Article and Find Full Text PDFEfficacy of bortezomib combined with Hyper-CVAD in adults with relapsed acute lymphoblastic leukemia or positive measurable residual disease; effect of bortezomib in leukemia.
Blood Res
January 2025
Hematology Laboratory, General Hospital of Mexico "Dr. Eduardo Liceaga", Mexico City, Mexico.
Purpose: Despite advances in the treatment of adult acute lymphoblastic leukemia (ALL), relapse remains the most significant challenge in improving prognosis. Measurable residual disease (MRD) assessment can predict bone marrow relapse based on MRD positivity. As access to innovative therapies remains limited because of the high cost, chemotherapy is the widely utilized treatment option.
View Article and Find Full Text PDFNon small cell lung cancer with SMARCA4 deficiency harboring rare EGFR mutations exhibited significant tumor response when treated with afatinib: a case report.
Front Med
January 2025
Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, China.
SMARCA4-deficient non small cell lung cancer (SMARCA4-dNSCLC) has recently garnered increasing attention due to its high malignancy and poor prognosis. The literature suggests that in non small cell lung cancer (NSCLC), the loss of SMARCA4 frequently co-occurs with mutations in KRAS, KEAP1, and STK11 rather than in EGFR, ALK, and ROS1. Herein, we present the first documented case of SMARCA4-dNSCLC accompanied with rare mutations of EGFR exon 20 S768I and exon 18 G719X.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!